The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of BCOP.
BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/
To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.
The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.
In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.
The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.
Target Audience: These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:
Acute Leukemia, Breast Cancer, Endometrial Cancer, Febrile Neutropenia, Gastric Cancer, Hematopoietic Cell Transplant, Interpretation of late-phase oncology trials, Lymphoma, Myeloma, Oncology Practice Management, Pancreatic Cancer, Pharmacogenomics, Prostate Cancer.
Oncology Home Study Syllabus Module A: Myeloma, Lymphoma, and Acute LeukemiaActivity Number: 0204-9999-25-949-H01-P
Contact Hour(s): 4.00
Activity Type: Application BasedLearning ObjectivesMyeloma
Costa LJ, Banerjee R, Mian H, et al. International Myeloma Working Group Immunotherapy Committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543-554.
- Develop recommendations for sequencing immunotherapies in the treatment of relapsed/refractory multiple myeloma based on the International Myeloma Working Group (IMWG) recommendations.
- Describe the impact of conventional myeloma therapies on subsequent antimyeloma immunotherapy.
- Select appropriate holding therapy and bridging therapy for patients receiving chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma based on IMWG recommendations.
Lymphoma
Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin’s lymphoma. N Engl J Med. 2024;391(15):1379-1389.
- Describe the S1826 trial of nivolumab, doxorubicin, vinblastine, and dacarbazine (N+AVD) for the treatment of advanced-stage classic Hodgkin’s lymphoma.
- Develop recommendations for the use of nivolumab, doxorubicin, vinblastine, and dacarbazine (N+AVD) for the treatment of advanced-stage classic Hodgkin’s lymphoma.
Acute Leukemia
Silva W, Rego E. How to manage Philadelphia-positive acute lymphoblastic leukemia in resource-constrained settings. Cancers (Basel). 2023;15(24):5783.
- Develop recommendations for the management of Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in resource-constrained settings.
- Select appropriate patients with Ph+ ALL to receive specific therapies based on genetic risk factors, according to clinical practice guidelines by Silva et al.
|
Oncology Home Study Syllabus Module B: Oncology Practice Management, Endometrial Cancer, and Interpretation of late-phase oncology trialsActivity Number: 0204-9999-25-950-H01-P
Contact Hour(s): 4.00
Activity Type: Application BasedLearning ObjectivesOncology Practice Management
Chan A, Ng DQ, Arcos D, et al. Electronic patient-reported outcome-driven symptom management by oncology pharmacists in a majority-minority population: an implementation study. JCO Oncol Pract. 2024;20(12):1744-1754.
- Describe the methodology for obtaining patient recorded outcomes (PRO) in a pharmacist-led initiative for oncology patients.
- Develop recommendations for the implementation of patient-specific education for patients who have submitted PRO data.
- Select appropriate patients to collect PRO data and who can benefit from individualized pharmacist-led education for their antineoplastic treatment.
Endometrial Cancer
Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol. 2024;42(3):283-299.
- Describe the study of durvalumab with or without olaparib in combination with chemotherapy for advanced or recurrent endometrial cancer.
- Develop recommendations for the use of durvalumab with or without olaparib in combination with chemotherapy for patients with advanced or recurrent endometrial cancer.
- Select appropriate patients to receive durvalumab with or without olaparib in combination with chemotherapy according to the results of DUO-E trial.
Interpretation of late-phase oncology trials
Lin TA, Sherry AD, Ludmir EB. Challenges, complexities, and considerations in the design and interpretation of late-phase oncology trials. Semin Radiat Oncol. 2023;33(4):429-437.
Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271-4281.
- Describe study design challenges and complexities for late-phase oncology trials.
- Interpret an oncology clinical trial evaluating darolutamide in combination with androgen-deprivation therapy for a patient with metastatic hormone-sensitive prostate cancer.
- Select appropriate statistical methods for a late-phase oncology trial.
|
Oncology Home Study Syllabus Module C: Febrile Neutropenia; Pancreatic, Prostate, and Breast CancersActivity Number: 0204-9999-25-951-H01-P
Contact Hour(s): 5.00
Activity Type: Application BasedLearning ObjectivesFebrile Neutropenia
Feng X, Qian C, Fan Y, et al. Is short-course antibiotic therapy suitable for Pseudomonas aeruginosa bloodstream infections in onco-hematology patients with febrile neutropenia? Results of a multi-institutional analysis. Clin Infect Dis. 2024;78(3):518-525.
- Describe the study of short-course antibiotic therapy for Pseudomonas aeruginosa bloodstream infections in malignant hematology patients with febrile neutropenia.
- Develop recommendations for the use of short-course antibiotic therapy in neutropenic patients with Pseudomonas aeruginosa bloodstream infections.
- Select appropriate patients to receive short-course antibiotic therapy based on the results of the study by Feng and colleagues.
Pancreatic Cancer
Nichetti F, Rota S, Ambrosini P, et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer a systematic review and meta-analysis. JAMA Netw Open. 2024;7(1):e2350756.
- Describe the meta-analysis comparing NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer.
- Develop recommendations for the use of NALIRIFOX, FOLFIRINOX, or gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer.
- Select appropriate patients to receive NALIRIFOX, FOLFIRINOX, or gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer.
Prostate Cancer
Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271-4281.
- Describe the study of darolutamide and androgen deprivation therapy (ADT) for the treatment of prostate cancer in patients with metastatic castration-sensitive disease.
- Select appropriate patients to receive darolutamide and ADT based on the results of the ARANOTE trial.
- Develop recommendations for the use of darolutamide and ADT in patients with metastatic castration-sensitive prostate cancer.
Breast Cancer
Bardia A, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor-2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2024;43(3):285-296.
- Describe the TROPION-Breast01 study of datopotamab deruxtecan for hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer.
- Develop recommendations for the use of datopotamab deruxtecan in patients with metastatic HR-positive, HER2-negative breast cancer.
- Select appropriate patients to receive drug datopotamab deruxtecan based on the results of the TROPION-Breast01 trial.
|
Oncology Home Study Syllabus Module D: Hematopoietic Cell Transplant, Gastric Cancer, and PharmacogenomicsActivity Number: 0204-9999-25-952-H01-P
Contact Hour(s): 4.00
Activity Type: Application BasedLearning ObjectivesHematopoietic Cell Transplant
Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766-1775.
- Describe the study of gilteritinib for post-transplant maintenance in acute myeloid leukemia.
- Develop recommendations for the use of post-transplant maintenance gilteritinib in acute myeloid leukemia.
- Select appropriate patients to receive post-transplant maintenance gilteritinib based on the results of the BMT CTN 1506/MORPHO trial.
Gastric Cancer
Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133-2141.
- Describe the GLOW trial comparing zolbetuximab and CAPOX to CAPOX alone as firstline chemotherapy for metastatic gastric and gastroesophageal cancers.
- Develop recommendations for the use of zolbetuximab and CAPOX as first-line treatment for metastatic gastric and gastroesophageal cancers based on the GLOW trial.
- Select appropriate patients to receive zolbetuximab and CAPOX based on the GLOW trial.
Pharmacogenomics
Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47-58.
- Describe the study of trastuzumab deruxtecan in patients with certain Her2-expressing solid tumors.
- Develop recommendations for the use of trastuzumab deruxtecan in patients with Her2-expressing solid tumors.
- Select appropriate patients with Her2 expression to receive trastuzumab deruxtecan based on the results of the DESTINY PanTumor02 phase II trial.
|
The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.